Tumor suppressor network dysregulation in neuroblastoma: molecular mechanisms and precision therapeutic opportunities.
Neuroblastoma is the most common extracranial solid malignancy in children and accounts for nearly 15% of paediatric cancer-related mortality, underscoring its substantial clinical burden. While oncogenic drivers, such as MYCN amplification and ALK mutations have been extensively investigated, accumulating genomic and epigenomic evidence indicates that disruption of tumor suppressor gene (TSG) networks plays a central role in neuroblastoma pathogenesis.
Neuroblastoma is the most common extracranial solid malignancy in children and accounts for nearly 15% of paediatric cancer-related mortality, underscoring its substantial clinical burden. While oncogenic drivers, such as MYCN amplification and ALK mutations have been extensively investigated, accumulating genomic and epigenomic evidence indicates that disruption of tumor suppressor gene (TSG) networks plays a central role in neuroblastoma pathogenesis.
What the study was
- Study design
- Review
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Frontiers in cell and developmental biology
Why it surfaced
Relevant Precision oncology and genomic medicine study (promising preliminary signal) meets standard-priority threshold.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.